Literature DB >> 15451174

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.

Fabien Zoulim1.   

Abstract

Chronic Hepatitis B virus (HBV) infections remain a major problem public health problem worldwide, as well as a therapeutic challenge for clinicians. This review focuses on the main viral and host determinants involved in HBV persistence in infected cells. The mechanism of HBV resistance to nucleoside analogs are described as well as the concept for multiple drug therapy and combination with immunostimulatory approaches.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15451174     DOI： 10.1016/j.antiviral.2004.07.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  36 in total

Review 1.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

Authors:  A-C Jacquard; M-N Brunelle; C Pichoud; D Durantel; S Carrouée-Durantel; C Trepo; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 3.  Emerging drugs for hepatitis B.

Authors:  Fabien Zoulim
Journal:  Expert Opin Emerg Drugs       Date:  2007-05       Impact factor: 4.191

4.  Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B.

Authors:  Tomasz I Michalak; Hong Zhang; Norma D Churchill; Torbjörn Larsson; Nils-Gunnar Johansson; Bo Oberg
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

5.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

6.  Management of hepatitis B in developing countries.

Authors:  Zaigham Abbas; Adeel R Siddiqui
Journal:  World J Hepatol       Date:  2011-12-27

7.  Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.

Authors:  Mariacarmela Solmone; Donatella Vincenti; Mattia Carlo Felice Prosperi; Alessandro Bruselles; Giuseppe Ippolito; Maria Rosaria Capobianchi
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.

Authors:  Hyo-Joong Kim; Ashoke Sharon; Chandralata Bal; Jianing Wang; Madhan Allu; Zhuhui Huang; Michael G Murray; Leda Bassit; Raymond F Schinazi; Brent Korba; Chung K Chu
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

9.  Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.

Authors:  Scott Bowden; Stephen Locarnini; Ting-Tsung Chang; You-Chen Chao; Kwang-Hyub Han; Robert G Gish; Robert A de Man; Miao Yu; Cyril Llamoso; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 10.  Current treatment indications and strategies in chronic hepatitis B virus infection.

Authors:  George V Papatheodoridis; Spilios Manolakopoulos; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.